Table 1.

Correlation of FXR mRNA expression with clinicopathological characteristics in patients with hepatocellular carcinoma

Variable	Relative FXR mRNA Levels
	n	Value	t	P
Age, yr			0.594	0.554
≤50	36	0.443 ± 0.018
>50	44	0.420 ± 0.031
Sex			0.054	0.956
Male	70	0.453 ± 0.022
Female	10	0.450 ± 0.065
α-Fetoprotein, ng/ml			−1.866	0.066
≤400	47	0.393 ± 0.025
>400	33	0.572 ± 0.108
Tumor size, cm			2.067	0.042
≤5	31	0.472 ± 0.027
>5	49	0.400 ± 0.022
Tumor number			−0.129	0.898
Single	63	0.445 ± 0.021
Multiple	17	0.451 ± 0.046
Barcelona Clinic Liver Cancer stage			2.076	0.041
0/A	13	0.507 ± 0.034
B/C	67	0.406 ± 0.020
Differentiation			2.128	0.037
Well/moderate	46	0.491 ± 0.028
Poor	34	0.403 ± 0.029
Portal vein thrombosis			0.841	0.402
Yes	54	0.465 ± 0.025
No	26	0.427 ± 0.037
Cirrhosis			−0.157	0.875
Yes	57	0.653 ± 0.020
No	23	0.660 ± 0.035
Encapsulation			2.255	0.027
Complete	37	0.492 ± 0.026
None or incomplete	43	0.414 ± 0.023

Values are means ± SE; n, number of subjects/group.

FXR, farnesoid X receptor.